Ge et al. examined three genome-wide association studies that included 3591 patients with bladder cancer and 1322 renal cell carcinoma patients and reported that the I157T variant found in CHEK2 was associated with decreased risk of bladder cancer and renal cell carcinoma [17]. Here, CHEK2 is linked to renal cell carcinoma.